Great News for Pericarditis Sufferers!
Kiniksa announced yesterday that the U.S. Food and Drug Administration (FDA) granted Orphan Drug designation for rilonacept for the treatment of pericarditis, which includes recurrent pericarditis.
The FDA grants Orphan Drug designation status to products that treat rare diseases, providing incentives to sponsors developing drugs or biologics. The FDA defines rare diseases as those affecting fewer than 200,000 people in the U.S. at the time of designation.
